Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma

Clin Cancer Res. 2008 Jun 15;14(12):3807-13. doi: 10.1158/1078-0432.CCR-08-0155.

Abstract

Purpose: Heterogeneous ribonucleoprotein K (hnRNP K) regulates thymidine phosphorylase (TP) mRNA stability. The aim of the present study was to analyze hnRNP K and TP expression in nasopharyngeal carcinoma (NPC) and to evaluate the prognostic and therapeutic potential of these two markers.

Experimental design: We analyzed hnRNP K and TP expression immunohistochemically in 121 clinically proven NPC cases. Statistical analyses were applied to correlate cytoplasmic hnRNP K with elevated TP expression and determine the prognostic significance of these parameters. The therapeutic implication of elevated TP expression was determined by measuring sensitivity of NPC cells to the TP-targeting drug, 5-fluoro-5'-deoxyuridine (5'-DFUR).

Results: There was a high correlation between cytoplasmic hnRNP K and high TP (P < 0.001). Both cytoplasmic hnRNP K and high TP were associated with poor overall survival (OS; P = 0.007 and P < 0.001, respectively) and distant metastasis-free survival (P = 0.003 and 0.001, respectively) of NPC patients. A multivariate analysis confirmed that both cytoplasmic hnRNP K and high TP are independent prognostic predictors for OS (P = 0.020 and 0.010, respectively). NPC cells expressing high TP were more sensitive to treatment with the TP-targeting drug, 5'-DFUR.

Conclusions: Cytoplasmic hnRNP K and high TP are associated with shorter OS and distant metastasis-free survival in NPC patients. In vitro experiments suggest that NPC tumors with high TP expression may be sensitive to 5'-DFUR treatment. Cytoplasmic hnRNP K and high TP may be potential prognostic and therapeutic markers for NPC, but additional validation studies are warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use
  • Biomarkers, Pharmacological*
  • Biomarkers, Tumor / metabolism
  • Biomarkers, Tumor / physiology*
  • Carcinoma / diagnosis*
  • Carcinoma / drug therapy
  • Carcinoma / metabolism
  • Carcinoma / mortality
  • Cytoplasm / metabolism
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Floxuridine / therapeutic use
  • Heterogeneous-Nuclear Ribonucleoprotein K / metabolism
  • Heterogeneous-Nuclear Ribonucleoprotein K / physiology*
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / diagnosis*
  • Nasopharyngeal Neoplasms / drug therapy
  • Nasopharyngeal Neoplasms / metabolism
  • Nasopharyngeal Neoplasms / mortality
  • Prognosis
  • Survival Analysis
  • Thymidine Phosphorylase / metabolism
  • Thymidine Phosphorylase / physiology*

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Pharmacological
  • Biomarkers, Tumor
  • Heterogeneous-Nuclear Ribonucleoprotein K
  • Floxuridine
  • Thymidine Phosphorylase
  • doxifluridine